Sino Biopharm's new drug "Liraglutide"has been approved for listing, officially entering the GLP-1 market. (Shanghai Securities News)
中国生物制药新药“利拉鲁肽”获批上市，正式进军GLP-1市场
Sino Biopharm's new drug "Liraglutide" has been approved for listing, officially entering the GLP-1 market.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.